Immunicom, Inc.
PrivateLast Round
Grant
Jun 14, 2022
Total Funding Raised
$14.85M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Immunicom, Inc. is a medical technology company that has developed a subtractive immunotherapy platform, Immunopheresis®, designed to treat cancer and other diseases by filtering harmful elements from the blood.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Hardware Sales, Hardware + Subscription, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Immunicom, Inc. Comparables
Compare Immunicom, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Aethlon Medical, Inc. | 78% | |
| MediSieve | 77% | |
| ExThera Medical | 71% |
Immunicom, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 14, 2022 | ||||
| Series B Extension | Sep 9, 2019 | ||||
| Series B | Jul 2, 2019 |
Key People
Founding team and executive leadership
Immunicom, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| NIH RADx | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 82% MoM, reaching 3.3K.
- Jul 25, 2026
Monthly visitors increased 38% MoM, reaching 1.8K.
Immunicom, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access